Navigation Links
QRxPharma Successfully Completes Comparative Phase 1 Proof-of-Concept Study for MoxDuo(R) CR Tablet Formulation
Date:5/10/2010

BEDMINSTER, N.J. and SYDNEY, May 10 /PRNewswire/ -- QRxPharma (ASX: QRX and OTCQX: QRXPY) announced today the successful outcome of a Phase 1 trial for MoxDuo CR, a controlled-release (CR) Dual-Opioid(TM) designed to provide 12 hours of pain relief in patients suffering from moderate to severe chronic pain (including cancer, lower back, osteoarthritis and neuropathic). The purpose of the trial was to determine which of the various experimental formulations provided the optimum duration of drug levels in the blood.

"The successful outcome of this trial reinforces QRxPharma's intellectual property that defines MoxDuo CR as a novel, controlled-release formulation for sustained pain relief. We are now one step closer to addressing the needs of chronic pain patients and entering the multi-billion dollar chronic pain market," said Dr. John Holaday, Managing Director and Chief Executive Officer, QRxPharma. "QRxPharma remains on track to finalising the MoxDuo CR tablet by the end of this year and to be in a position to initiate Phase 2 trials shortly thereafter."

The Phase 1 trial, a single dose crossover design, was conducted in 14 normal healthy volunteers at one U.S. clinical research site. This study compared the rate at which key components of the CR formulation were absorbed, distributed, metabolised and eliminated by the body to the pharmacokinetic profile of Oxycontin® 20 mg (sustained release oxycodone).

Pharmacokinetic results are encouraging, and the profile is consistent with expectations for a twice-daily formulation. Data from this study will significantly aid QRxPharma and its manufacturing partner, Patheon Inc., in finalising the target release profile for the product and finalising the composition of prototype MoxDuo CR tablets.

The Company's MoxDuo® product portfolio includes both immediate and controlled release, as well as intravenous formulations. "Our goal is to provide physicians and patients with a variety of complementary Dual-Opioids for managing moderate to severe pain from hospital to home," added Holaday.


'/>"/>
SOURCE QRxPharma
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. QRxPharma Doses First Patients in Phase III Clinical Trial Program for its Dual Opioid Pain Therapy
2. QRxPharma Releases Successful Phase 3 Study Results for Dual Opioid Pain Therapy
3. QRxPharma Releases Additional Phase 3 Data for Q8003IR Dual Opioid Pain Therapy
4. QRxPharma Successfully Completes Comparative Study for Dual-Opioid(TM) Pain Therapy
5. QRxPharma Inks Deal with Patheon for the Manufacture of MoxDuo(TM)CR
6. QRxPharma Limited Announces A$21.6 Million Fully Underwritten Capital Raising
7. QRxPharma Initiates Second Pivotal Phase 3 Study of MoxDuo(TM)IR Dual-Opioid(TM) for NDA Submission
8. QRxPharma Limited and China Aoxing Pharmaceutical Company Announce Strategic Alliance for Development of MoxDuo(R)IV
9. QRxPharma Releases Additional Pivotal Phase 3 Combination Rule Study Data for MoxDuo(R)IR in Patients with Post-Surgical Pain
10. Harvard Medical School-Partners HealthCare Center for Genetics and Genomics Successfully Completes Evaluation of AutoGenomics 2C9-VKORC1 Panel to Assess Warfarin Sensitivity
11. TaiGen Biotechnology Successfully Completes Patient Recruitment for Phase II Trial of Nemonoxacin for Treatment of Adult Community Acquired Pneumonia (CAP)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/16/2017)... years ago today, the Monterey Pop Festival opened its gates ... Francisco "Summer of Love."  To celebrate the anniversary, Northern Light® ... market research portals that it will begin delivering to customers ... "Summer of Love (For Our Customers)."  ... Northern Light ...
(Date:6/14/2017)... WINSTON-SALEM, N.C. , June 14, 2017  In ... the Creative Startups pitch competition and came ... virtual reality platform is described by Forbes as "entering ... the American Medical Association as teaching "empathy to medical ... success, the startup was recently named a finalist for ...
(Date:6/11/2017)... 2017  Eli Lilly and Company (NYSE: LLY ... studies of galcanezumab, an investigational treatment for the prevention ... several key secondary endpoints for galcanezumab compared to placebo ... (EVOLVE-1, EVOLVE-2 and REGAIN) will be presented today at ... Boston . "The ...
Breaking Medicine Technology:
(Date:6/22/2017)... ... 22, 2017 , ... The VA Maryland Health Care System ... awarded the Baltimore VA Medical Center, a division of the VA Maryland Health ... to promote waste reduction and promote recycling. Also, Practice Greenhealth has recognized ...
(Date:6/20/2017)... ... June 20, 2017 , ... TwelveStone Health Partners, ... a Nashville-based private equity firm, has invested $3.35 million in the company. ... and Claritas Capital offers the smart money, speed to market and accountability we ...
(Date:6/20/2017)... (PRWEB) , ... June 20, 2017 , ... ... health science curriculum , is pleased to announce a new online course entitled ... online course provides practical insights and evidence-based strategies for achieving optimal well-being and ...
(Date:6/20/2017)... ... June 20, 2017 , ... ... that the introduction of school choice can promote economic development in economically distressed ... that has, according to the report, contributed to the economic development of the ...
(Date:6/20/2017)... ... 2017 , ... Leading dental clinicians, Drs. Ashlyn Price, Autumn Mayers and Ron ... Anatomage systems. With advanced digital images and modeling capabilities, the dentists identify all of ... restore oral health for those who are missing teeth in Midlothian, VA. ...
Breaking Medicine News(10 mins):